TRIM68

Across TCGA pan-cancer cohorts, TRIM68 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRIM68 data layer compared with 30 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TRIM68 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TRIM68 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where TRIM68 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.543	1.000	<.001	74	view →
LSCC	DFS	Median	All	0.585	0.819	.006	17	view →
PDAC	DFS	Median	III,IV	0.441	1.000	.008	16	view →
UCEC	OS	Tertile	III,IV	0.290	1.000	.029	8	view →
LUAD	DFS	Tertile	II,III,IV	0.864	0.201	.018	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRIM68–CCRCC (OS)

Open the CCRCC breakdown →